#therapeutics - Techseriesinsight

May 27, 2025
PRNewswire
Biotechnology

Sapience Therapeutics Announces Participation in the Jefferies Global Healthcare Conference

Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced its participation...

May 16, 2025
PRNewswire
Biotechnology

Neutron Therapeutics and Helsinki University Hospital Treat First Head and Neck Cancer Patients Using Accelerator-Based Boron Neutron Capture Therapy

Neutron Therapeutics LLC and the Helsinki University Hospital announce that they have treated the first cancer patients in a European hospital with accelerator-based boron neutron capture therapy (BNCT). This milestone marks...

May 8, 2025
PRNewswire
Biotechnology

Ratio Therapeutics to Establish New Radiopharmaceutical Manufacturing Facility

Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, today announced that it entered into an agreement with the...

May 8, 2025
PRNewswire
Biotechnology

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the third patient in Cohort 4 of its Phase...

May 7, 2025
PRNewswire
Biotechnology

BioVaxys and Sona Nanotech Enter Research Collaboration

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”) and Sona Nanotech Inc. (CSE: SONA) (OTC: SNANF) (“Sona”) announce today that they have entered into a Research Agreement (“Agreement”) to...

May 6, 2025
PRNewswire
Biotechnology

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer’s Regorafenib Effect in GI Cancer Models

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that the first set of oncology studies has...